Infection tracking in myeloma patients on elranatamab
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study watches patients with advanced multiple myeloma who are receiving a newer drug called elranatamab in everyday clinical practice. The main goal is to keep track of infections that may happen during treatment, so doctors can better understand and manage them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have relapsed and refractory multiple myeloma, meaning your disease has progressed on or within 60 days of your last treatment.
- You have had at least three prior lines of therapy, including an immunomodulatory agent (e.g., lenalidomide), a proteasome inhibitor (e.g., bortezomib), and an anti-CD38 antibody (e.g., daratumumab).
- You are currently being treated with elranatamab as part of your routine clinical care.
- You are willing to provide written consent to participate in this observation study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests whether giving letermovir (a medication to prevent CMV infection) is safe and effective for people with relapsed/refractory multiple myeloma who are starting elranatamab therapy. It is for patients who have already had several prior treatments and have been exposed to CMV in the past.
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
Hear when a new Multiple Mieloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.